Thyroid Nodules: Are We Overdiagnosing Cancer?
"A closer look at Non-Invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) and its impact on pre-operative assessment."
The diagnosis and management of thyroid nodules have evolved significantly in recent years. One area of particular interest and concern is the classification and treatment of Non-Invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features, or NIFTP. This type of thyroid tumor, while having some characteristics that resemble cancer, is generally considered indolent, meaning it grows slowly and is less aggressive than traditional thyroid cancers.
Historically, NIFTP nodules were often treated with total thyroidectomy, a surgical procedure that removes the entire thyroid gland. However, the understanding of NIFTP as a less aggressive entity has led to a re-evaluation of treatment strategies. Current recommendations often favor a more conservative approach, such as hemithyroidectomy, which removes only half of the thyroid gland. This change aims to reduce the burden of a cancer diagnosis on patients and avoid unnecessary extensive surgery and its potential complications.
Despite these advances, the diagnosis of NIFTP remains challenging. Distinguishing NIFTP from more aggressive forms of thyroid cancer requires careful examination of the nodule's cellular structure. The concern is that over-interpreting certain nuclear features during pre-operative assessments could lead to an overdiagnosis of malignancy, resulting in potentially unnecessary surgery.
NIFTP’s Impact on Thyroid Nodule Management
The introduction of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has affected the clinical management of thyroid nodules, and revised diagnostic criteria emphasize applying stringent histomorphologic requirements. A 2024 study reviewed radiological and pathological data for consecutive NIFTP cases in one health system from January 2018 through December 2022. A separate meta-analysis set out to estimate NIFTP incidence worldwide by reviewing published data, reflecting that the impact of reclassification depends on how often the entity occurs in different populations.
Diagnosis and Remaining Challenges
NIFTP was proposed as a new name for the lesion formerly called noninvasive encapsulated follicular variant of papillary thyroid carcinoma, following an international multicenter consensus that described indolent behavior without metastasis or recurrence. Diagnosis depends on morphologic criteria, and conceptual and morphologic challenges remain; one review characterizes NIFTP as an initial step toward a more biologically accurate approach to thyroid neoplasia. Reclassification also affects the performance of molecular tests used to triage indeterminate nodules.
Navigating NIFTP: Understanding the risk of overdiagnosis
A recent study from Glasgow and Clyde provides valuable insights into the pre-operative assessment of NIFTPs. The researchers reviewed the cytology and ultrasonography results of 12 patients diagnosed with NIFTP between September 2016 and March 2018. This retrospective analysis aimed to estimate the risk of overcalling NIFTPs as malignant based on pre-operative assessments.
- Cytological findings: Most NIFTPs displayed a microfollicular architecture with subtle nuclear changes. In this study, seven cases were reported as Thy3f (equivalent to SFN/FN in TBSRTC), four as Thy3a (equivalent to AUS/FLUS), and one was insufficient (Thy1).
- Ultrasonography results: The majority of nodules (83%) were classified as U3 (indeterminate), mostly solid, isoechoic nodules. Only two (17%) were classified as U4 (suspicious).
- Study aim: To estimate the pre-operative risk of overcalling NIFTPs malignant.
Limits of Preoperative Identification
NIFTP is defined by follicular architecture and papillary-like nuclear features, while lacking classic papillary carcinoma features such as papillae or psammoma bodies; the cited 2024 source also says the diagnosis excludes cases with high-risk mutations. A practical limitation is that fine-needle aspirates, often the first specimens reviewed, cannot establish whether the tumor capsule is invaded. This makes it difficult to distinguish NIFTP from papillary thyroid carcinoma on cytology alone.
Imaging and Clinical Comparisons
In one comparison with non-NIFTP papillary thyroid carcinoma, NIFTP nodules were more often isoechoic (69.2% versus 17.4%) and had smooth borders (92.3% versus 31.1%); they were also more often categorized as TI-RADS 2, 3, or 4a. Cytologically, NIFTP cases were mainly classified as AUS/FLUS, FN, or SusM under the Bethesda system. In a separate pediatric institutional series, all three patients with NIFTP had unifocal tumors classified T2 or lower and had no lymph-node or distant metastases.
The Path Forward: Reducing Overdiagnosis in Thyroid Nodules
While the Glasgow and Clyde study, along with other research, suggests that most NIFTPs are not diagnosed as malignant preoperatively, it is crucial to remain vigilant. Encouraging the correlation of cytology with ultrasound, combined with molecular testing when appropriate, can further refine diagnostic accuracy and help avoid false-positive diagnoses. By carefully considering all available information, healthcare professionals can provide the most appropriate and personalized care for individuals with thyroid nodules.
Why NIFTP Was Named
An international expert group led by Prof. Yuri Nikiforov created the NIFTP category in response to the indolent behavior of encapsulated follicular variant of papillary thyroid carcinoma. The diagnostic consensus was based on analysis of 268 cases. The new name identifies a distinct entity as a neoplasm rather than labeling it as carcinoma.
Treatment Planning and Avoiding Overtreatment
A 2024 case report describes NIFTP as a diagnosis that can help avoid overtreating nodules that may be managed with lobectomy alone. Although the diagnosis is made after surgery, the report says comprehensive preoperative evaluation may raise suspicion of NIFTP and support a more careful treatment plan. Another case-report source characterizes NIFTP as a tumor that can mimic papillary thyroid carcinoma while having an indolent course and excellent prognosis, and stresses accurate diagnosis to prevent overtreatment.